Array Instruments

Array Instruments Market Outlook

The global Array Instruments Market was valued at approximately USD 3.2 billion in 2025 and is projected to reach USD 5.5 billion by 2035, growing at a CAGR of 5.9% during the forecast period. This growth can be attributed to the increasing demand for advanced diagnostic techniques and the rise in research activities across genomics and proteomics. Furthermore, several healthcare initiatives aimed at enhancing disease diagnostics and personalized medication are expected to bolster the array instruments market. The growing prevalence of chronic diseases necessitating extensive research and precise diagnostics is another factor driving market expansion. Additionally, the advancements in microarray technology, which allow for high-throughput analysis and detailed insights into genetic information, are fueling market growth.

Growth Factor of the Market

As healthcare continues to evolve, the demand for array instruments has seen a significant uptick, primarily driven by enhanced research capabilities and innovations in biotechnology. The surge in funding for genomics and proteomics research, coupled with the increasing prevalence of genetic disorders, has catalyzed the adoption of these tools. Moreover, with the rising trend of personalized medicine, healthcare providers are keen on utilizing array technologies to develop tailored treatment plans that suit individual patients' genetic makeups. The integration of artificial intelligence and machine learning into array technology has also opened new avenues for data analysis, making it easier for researchers to derive meaningful insights from complex datasets. Furthermore, the expansion of the healthcare infrastructure globally, particularly in emerging economies, is expected to further facilitate the growth of the array instruments market.

Key Highlights of the Market

• Rapid advancements in microarray technology are leading to increased adoption in various fields.
• Growing investment in research and development initiatives is propelling market growth.
• Personalized medicine is becoming a significant focus, necessitating the use of array instruments.
• The rise in chronic diseases worldwide is driving the need for advanced diagnostic tools.
• Emerging markets are witnessing a surge in healthcare infrastructure improvements, enhancing market potential.

By Product Type

DNA Microarrays:

DNA microarrays are one of the most widely used array instruments that allow researchers to analyze the expression levels of thousands of genes simultaneously. These arrays facilitate comparative genomic studies and are crucial in applications such as gene expression profiling, genotyping, and mutation detection. The high-throughput nature of DNA microarrays makes them invaluable in research settings, particularly in genomics and molecular biology. Moreover, advancements in DNA synthesis techniques and the decreasing costs associated with microarray production have contributed to their increasing adoption. As a result, the market for DNA microarrays is anticipated to witness significant growth over the forecast period.

Protein Microarrays:

Protein microarrays are emerging as powerful tools for proteomics research, offering the ability to analyze interactions between proteins and their respective ligands. These instruments provide a platform for the simultaneous detection of various proteins and allow for the study of protein expression levels, functionality, and interactions. The increasing prevalence of diseases linked to protein malfunction, such as cancers and autoimmune diseases, has driven the demand for protein microarrays in clinical research and diagnostics. As the understanding of proteomics expands, the protein microarray segment is expected to see substantial growth, driven by innovations in assay technologies and the integration of these tools into clinical workflows.

Cell Microarrays:

Cell microarrays present a novel approach for high-throughput analysis of cellular behaviors and characteristics. By enabling researchers to study various cell types and their responses to different stimuli or treatments, cell microarrays are becoming integral in drug discovery and development processes. The ability to analyze cellular responses in a controlled environment allows for more accurate prediction of drug efficacy and toxicity. As pharmaceutical companies increasingly look to streamline their drug development processes, the demand for cell microarrays is likely to grow significantly. The segment is poised for expansion with advancements in cell culture techniques and automation technologies.

Tissue Microarrays:

Tissue microarrays provide a means to analyze multiple tissue samples simultaneously, making them a powerful tool in histopathology and cancer research. These arrays allow for the study of tissue expression patterns, aiding in the identification of biomarkers for various diseases. The ability to conduct high-throughput analysis of tissue samples has made tissue microarrays invaluable in diagnostic research and clinical oncology. With ongoing advancements in immunohistochemistry and an increasing focus on personalized medicine, the tissue microarray segment is anticipated to witness considerable growth as researchers seek to better understand disease mechanisms and develop effective therapies.

Chemical Compound Microarrays:

Chemical compound microarrays are gaining traction as a high-throughput method for screening small molecules and studying their biological interactions. These arrays facilitate drug discovery by enabling researchers to assess the effects of numerous compounds on specific biological systems simultaneously. As the pharmaceutical industry faces pressure to develop new drugs more efficiently, the utilization of chemical compound microarrays is becoming increasingly prevalent. This segment is expected to experience robust growth, driven by innovations in array technology and the need for novel therapeutic agents to combat diseases.

By Application

Drug Discovery:

Drug discovery remains one of the most prominent applications of array instruments, with these tools aiding in the identification and development of new therapeutic agents. The capacity of array technology to perform high-throughput screening allows researchers to evaluate thousands of compounds and their effects on biological targets in a fraction of the time required by traditional methods. This efficiency not only accelerates the drug discovery process but also reduces costs, making it essential for pharmaceutical companies. As the demand for innovative medications continues to rise, driven by factors such as an aging population and the prevalence of chronic diseases, the drug discovery application of array instruments is expected to see substantial growth over the forecast period.

Genomics:

In the realm of genomics, array instruments play a pivotal role in understanding genetic variations and gene expression profiles. The ability to analyze vast amounts of genomic data rapidly has made these tools indispensable in research settings. With the growing prevalence of genetic disorders and an increasing focus on personalized medicine, the demand for genomic array technology is surging. Researchers are leveraging these instruments to uncover genetic links to diseases, paving the way for targeted therapies and interventions. As advancements in sequencing technologies emerge, the genomics application segment is expected to witness continuous growth, reflecting the ongoing evolution of genetic research.

Proteomics:

Proteomics, the study of proteins and their functions, is another critical application of array instruments, enabling scientists to explore complex biological systems. Proteomics research has gained momentum in recent years, with an increasing focus on understanding diseases at the molecular level. Array technology facilitates the simultaneous analysis of numerous proteins, providing insights into their roles in health and disease. The demand for proteomics solutions is expected to rise significantly as researchers seek to understand the proteome's dynamics and interactions. This growing interest, coupled with advancements in array technology, will likely sustain the growth of the proteomics application segment in the coming years.

Diagnostics:

Array instruments have found extensive use in diagnostics, particularly in detecting diseases at an early stage and monitoring treatment responses. The ability to conduct high-throughput analysis allows for the development of sophisticated diagnostic tests that can provide insights into patients' health status. As healthcare systems increasingly prioritize early disease detection and personalized treatment plans, the demand for diagnostic array technology is poised for growth. Furthermore, the increasing integration of molecular diagnostics into clinical practice enhances the relevance of array instruments in healthcare, providing a promising outlook for this application segment.

Biomarker Discovery:

The discovery of biomarkers is a crucial area where array instruments are making significant strides. These tools enable researchers to identify and validate biomarkers that can indicate the presence of diseases or predict treatment responses. The importance of biomarkers in drug development and personalized medicine has fueled research efforts in this area. As regulatory agencies emphasize the need for robust biomarker studies, the demand for array technologies that facilitate these discoveries is set to rise. This trend is expected to foster the growth of the biomarker discovery application segment, opening new avenues for research and clinical applications.

By Distribution Channel

Online Stores:

The online distribution channel has become a prominent avenue for purchasing array instruments, providing a platform for accessibility and convenience. With the increasing trend of e-commerce in the healthcare sector, researchers and institutions can easily compare products, read reviews, and make informed purchasing decisions from the comfort of their offices or labs. Online stores often offer a wide range of products, including the latest advancements in array technology, making it easier for customers to find what they need. The continued growth of online purchasing behavior among research institutions is expected to bolster this distribution channel's market share.

Biotechnology Companies:

Biotechnology companies play a crucial role in the distribution of array instruments, often developing and supplying cutting-edge technologies to researchers and clinicians. These companies are at the forefront of innovation, continually improving array technologies to meet the evolving needs of the market. Partnerships with research institutions and healthcare providers further enhance their reach, allowing for tailored solutions and improved customer service. As the biotechnology sector continues to expand, particularly in response to the demand for advanced diagnostics and therapeutics, the market's reliance on biotechnology companies for array instruments is anticipated to grow.

Research Institutes:

Research institutes are significant users and distributors of array instruments, often employing these tools in various studies across genomics, proteomics, and diagnostics. These institutions contribute to advancing knowledge and technology in the field, frequently collaborating with manufacturers to develop customized solutions that meet their specific research needs. Furthermore, many research institutes are involved in the commercialization of their findings, leading to the establishment of spin-off companies that also distribute array technologies. Consequently, the growing focus on research and innovation within academia is expected to sustain the demand for array instruments through research institutes.

Hospitals & Clinics:

Hospitals and clinics increasingly recognize the value of array instruments in enhancing diagnostic capabilities and patient care. These facilities utilize array technologies to perform a variety of tests, including genetic testing and biomarker analysis, which are essential for effective disease management. The integration of advanced diagnostic tools into clinical workflows has become more prevalent, driven by the need for precision medicine and personalized care. As healthcare providers strive to improve patient outcomes through accurate and timely diagnosis, the demand for array instruments in hospitals and clinics is expected to grow steadily.

Diagnostic Laboratories:

Diagnostic laboratories are integral to the distribution of array instruments, utilizing these tools to provide accurate and timely diagnostic services. The need for high-throughput testing in clinical laboratories has increased significantly, leading to a greater reliance on array technologies to analyze samples efficiently. Through the adoption of advanced array instruments, diagnostic laboratories can offer comprehensive testing services that meet the growing demands of healthcare providers and patients alike. As the importance of molecular diagnostics continues to rise, this distribution channel is poised for growth, driven by the expanding capabilities of array technologies.

By Technology Type

Oligonucleotide Arrays:

Oligonucleotide arrays are a vital technology in the array instruments market, allowing for the analysis of nucleic acids and the study of gene expression profiles. These arrays enable researchers to detect specific DNA and RNA sequences, making them indispensable tools in genomics and molecular biology. The ongoing advancements in oligonucleotide synthesis and array fabrication are enhancing the sensitivity and specificity of these tools. Consequently, the demand for oligonucleotide arrays is expected to increase significantly as researchers seek to unravel the complexities of genetic information and its implications for health and disease.

Peptide Arrays:

Peptide arrays are gaining prominence in proteomics research, providing a platform to study protein interactions and functionality. These arrays facilitate the synthesis of numerous peptides on a single chip, allowing researchers to evaluate their biological activity efficiently. The growing interest in understanding protein interactions, especially in drug discovery and biomarker identification, is driving the demand for peptide arrays. As advancements in peptide synthesis and array technologies continue, this segment is likely to see robust growth, particularly in applications related to personalized medicine and therapeutic development.

Antibody Arrays:

Antibody arrays are essential tools for studying protein expression and interactions, providing critical insights into various biological processes. These arrays utilize immobilized antibodies to capture target proteins, allowing for the simultaneous analysis of multiple proteins in a single assay. The demand for antibody arrays is increasing substantially, driven by the growing need for comprehensive proteomic analysis and the identification of biomarkers for diseases. As the focus on precision medicine intensifies, antibody arrays are expected to play a significant role in advancing research and diagnostic capabilities in the healthcare sector.

Small Molecule Arrays:

Small molecule arrays serve as a powerful platform for drug discovery and development, enabling researchers to assess the effects of numerous compounds on biological targets simultaneously. These arrays allow for high-throughput screening of potential therapeutic agents, driving the efficiency of the drug development process. The increasing focus on identifying novel drug candidates, especially for complex diseases, is boosting the demand for small molecule arrays within the pharmaceutical industry. As advancements in array technology continue to emerge, this segment is likely to experience significant growth, supporting the evolving landscape of drug discovery.

Carbohydrate Arrays:

Carbohydrate arrays are becoming increasingly relevant in the study of glycomics, offering insights into carbohydrate-protein interactions and their implications in various biological processes. These arrays enable researchers to analyze glycan structures and their functionalities, which is essential for understanding diseases such as cancer and diabetes. The growing interest in glycomics research and the need for novel therapeutic agents targeting carbohydrate interactions are driving the demand for carbohydrate arrays. As the field of glycomics continues to expand, the carbohydrate array segment is expected to witness notable growth, reflecting the broader trends in bioscience research.

By Region

The Array Instruments Market exhibits significant regional variation, with North America leading the market due to its robust healthcare infrastructure and ongoing research initiatives. The region is estimated to account for over 40% of the global market share, driven by increasing investment in biotechnology and pharmaceuticals. The presence of numerous leading companies and research institutions further supports the growth of this market segment. The CAGR for North America is projected to be approximately 6.2% during the forecast period, fueled by technological advancements and a growing focus on personalized medicine.

Europe is the second-largest market for array instruments, with a projected market share of around 30%. The region is witnessing significant growth due to increasing research funding and initiatives aimed at enhancing healthcare diagnostics. The rising prevalence of chronic diseases and genetic disorders, along with advancements in genomic and proteomic research, are pivotal factors driving the European market. Meanwhile, the Asia Pacific region is expected to exhibit the highest growth rate, with a CAGR of over 7% between 2025 and 2035. The growing healthcare infrastructure, increased investment in research and development, and a rising focus on advanced diagnostic technologies contribute to the Asia Pacific's promising outlook.

Opportunities

The Array Instruments Market is poised for numerous opportunities as technological advancements and innovations continue to evolve within the healthcare and research sectors. One of the most significant opportunities lies in the integration of artificial intelligence and machine learning in array technology, enhancing data analysis and interpretation capabilities. This integration can empower researchers to derive actionable insights from complex datasets more efficiently, ultimately leading to faster and more accurate diagnoses and therapeutic discoveries. Furthermore, the increasing trend of personalized medicine presents a substantial opportunity for array instruments, as healthcare providers look to tailor treatments based on individual genetic profiles and biomarkers.

Moreover, the growing prevalence of chronic diseases, such as diabetes, cancer, and cardiovascular disorders, is creating a pressing need for advanced diagnostic and research solutions. Array instruments play a pivotal role in identifying biomarkers, understanding disease mechanisms, and facilitating drug discovery, making them integral to addressing these healthcare challenges. Additionally, emerging markets, particularly in Asia Pacific and Latin America, present significant growth opportunities due to expanding healthcare infrastructures and increasing investments in research initiatives. As these regions enhance their focus on biotechnology and personalized medicine, the demand for array instruments is expected to rise, driving overall market growth.

Threats

Despite the promising outlook for the Array Instruments Market, several threats could impact its growth trajectory. One of the primary concerns is the rapid pace of technological advancements, which can lead to an oversaturation of the market with various products and solutions. As new technologies emerge, companies may struggle to differentiate their offerings, leading to intense competition and price wars that could impact profitability. Additionally, the high cost associated with advanced array technologies may deter smaller research institutions and startups from adopting these tools, limiting the overall market potential.

Moreover, regulatory challenges pose a significant threat to the array instruments market, as the approval processes for new diagnostic tools and technologies can be lengthy and cumbersome. Stringent regulations and guidelines may hinder the timely introduction of innovative products into the market, delaying their commercial viability. Furthermore, changes in healthcare policies and reimbursement models could affect the adoption of array technologies within clinical settings, posing additional challenges to market growth. Companies must navigate these regulatory hurdles and adapt to evolving market conditions to remain competitive and capitalize on growth opportunities.

Competitor Outlook

• Illumina, Inc.
• Affymetrix, Inc. (Thermo Fisher Scientific)
• Agilent Technologies, Inc.
• Roche Diagnostics
• PerkinElmer, Inc.
• Bio-Rad Laboratories, Inc.
• Arrayit Corporation
• Merck KGaA
• QIAGEN N.V.
• GE Healthcare
• Invitrogen (Thermo Fisher Scientific)
• Enzo Life Sciences, Inc.
• F. Hoffmann-La Roche Ltd.
• Pacific Biosciences of California, Inc.
• Sabiosciences Corporation

The competitive landscape of the Array Instruments Market is characterized by the presence of numerous well-established players and emerging companies. Leading firms such as Illumina, Inc. and Affymetrix, Inc. are at the forefront of innovation, continuously advancing array technology to meet the evolving needs of researchers and clinicians. These companies invest heavily in research and development to enhance product offerings and maintain a competitive edge. Furthermore, strategic collaborations and partnerships with research institutions and healthcare providers enable these organizations to expand their market reach and strengthen their product portfolios, further intensifying competition within the industry.

In addition to established players, several emerging companies are making inroads into the array instruments market, introducing novel products and solutions that cater to niche applications. For example, Arrayit Corporation specializes in microarray technology and offers a range of products tailored for research and clinical applications. As these smaller companies leverage innovative approaches and technologies, they contribute to the dynamic landscape of the market, creating both opportunities and challenges for larger, established firms.

Key competitors such as Agilent Technologies and Roche Diagnostics are also focusing on expanding their product lines and enhancing their service capabilities. Agilent, for instance, offers a wide range of array technologies, including oligonucleotide and protein arrays, catering to diverse research needs. Roche Diagnostics, on the other hand, integrates its array technology into its comprehensive diagnostic solutions, providing healthcare providers with valuable tools for patient management. As these companies continue to innovate and adapt to market demands, they play a significant role in shaping the future of the Array Instruments Market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Merck KGaA
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 QIAGEN N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 GE Healthcare
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Illumina, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 PerkinElmer, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Roche Diagnostics
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Arrayit Corporation
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Enzo Life Sciences, Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 F. Hoffmann-La Roche Ltd.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Sabiosciences Corporation
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Agilent Technologies, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Bio-Rad Laboratories, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Invitrogen (Thermo Fisher Scientific)
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Pacific Biosciences of California, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Affymetrix, Inc. (Thermo Fisher Scientific)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Array Instruments Market, By Application
    • 6.1.1 Drug Discovery
    • 6.1.2 Genomics
    • 6.1.3 Proteomics
    • 6.1.4 Diagnostics
    • 6.1.5 Biomarker Discovery
  • 6.2 Array Instruments Market, By Technology Type
    • 6.2.1 Oligonucleotide Arrays
    • 6.2.2 Peptide Arrays
    • 6.2.3 Antibody Arrays
    • 6.2.4 Small Molecule Arrays
    • 6.2.5 Carbohydrate Arrays
  • 6.3 Array Instruments Market, By Distribution Channel
    • 6.3.1 Online Stores
    • 6.3.2 Biotechnology Companies
    • 6.3.3 Research Institutes
    • 6.3.4 Hospitals & Clinics
    • 6.3.5 Diagnostic Laboratories

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Array Instruments Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Array Instruments market is categorized based on

By Application

• Drug Discovery
• Genomics
• Proteomics
• Diagnostics
• Biomarker Discovery

By Distribution Channel

• Online Stores
• Biotechnology Companies
• Research Institutes
• Hospitals & Clinics
• Diagnostic Laboratories

By Technology Type

• Oligonucleotide Arrays
• Peptide Arrays
• Antibody Arrays
• Small Molecule Arrays
• Carbohydrate Arrays

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Illumina, Inc.
• Affymetrix, Inc. (Thermo Fisher Scientific)
• Agilent Technologies, Inc.
• Roche Diagnostics
• PerkinElmer, Inc.
• Bio-Rad Laboratories, Inc.
• Arrayit Corporation
• Merck KGaA
• QIAGEN N.V.
• GE Healthcare
• Invitrogen (Thermo Fisher Scientific)
• Enzo Life Sciences, Inc.
• F. Hoffmann-La Roche Ltd.
• Pacific Biosciences of California, Inc.
• Sabiosciences Corporation